European Commission logo
français français
CORDIS - Résultats de la recherche de l’UE
CORDIS

Protein Ruler to Create Affordable Biosensor Diagnosis for the Many

Objectif

Ovarian cancer is the most common malignancy of the female reproductive system worldwide, and the leading cause of death from
gynecological cancer. However, if diagnosed during the early stages, patients have a good prognosis, at around 90% 5-year survival
rate. Despite its lethality, there are currently no effective simple tests for diagnosis nor population-based screening techniques for
ovarian cancer. Emerging tests detecting cancer biomarkers have the potential for greatest impact for surveillance and early
detection, such as the FDA approved CA125 and HE4 biomarkers. Importantly, because the levels of these biomarkers are not the
same among all healthy females and increase with age, these tests should be quantitative. Current quantitative diagnostic tests for
CA125 and HE4 detection are expensive, require high-cost infrastructures and trained professionals. Therefore, there is an urgent
need for developing cheap, reliable, easy-to-use quantitative tests for ovarian cancer biomarkers. In this project, ground-breaking innovating research will give rise to novel technology, enabling the detection of cancer biomarkers in a manner that is quantitative, and yet
simple, portable and cheap.

Mots‑clés

Institution d’accueil

LUNDS UNIVERSITET
Contribution nette de l'UE
€ 150 000,00
Adresse
Paradisgatan 5c
22100 Lund
Suède

Voir sur la carte

Région
Södra Sverige Sydsverige Skåne län
Type d’activité
Higher or Secondary Education Establishments
Liens
Coût total
Aucune donnée

Bénéficiaires (1)